Status:
COMPLETED
Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Thyroid Neoplasms
Eligibility:
MALE
18-55 years
Phase:
NA
Brief Summary
Papillary cancer may affect patients of any age,with a good prognosis. Most of young patients may hence procreate as often as the general population.131iodine is an essential tool during treatment of ...
Detailed Description
Papillary cancer may affect patients of any age,with a good prognosis. Most of young patients may hence procreate as often as the general population. 131iodine is an essential tool during treatment o...
Eligibility Criteria
Inclusion
- Men from 18 to 55 years treated by thyroid surgery for papillary carcinoma followed by iodine 131 radiotherapy
- informed consent
Exclusion
- The patients under supervision (guardianship), under guardianship.
- Patients of less than 18 years old and furthermore of 55 years old
- Hypogonadism known or bare during the hormonal balance sheet of inclusion.
- The patients with a history of definitive azoospermia·
- Azoospermia at baseline spermogram
- Chemotherapy or radiotherapy history
- The patients exposed to toxic substance for the spermatogenesis
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01150318
Start Date
January 1 2006
End Date
June 1 2010
Last Update
August 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Antoine Hospital, Endocrinology Unit
Paris, France, 75012